Lundbeck Steps Up Chinese Operations; Revises Lexapro Terms With J&J
This article was originally published in PharmAsia News
Executive Summary
Danish drug maker Lundbeck is increasing its sales force in China and revising its licensing agreement with partner Xian-Janssen - Johnson & Johnson's China subsidiary - to co-market its top-selling antidepressant Lexapro (escitalopram) in China
You may also be interested in...
Lundbeck Establishes Shanghai Research Center To Find More Chinese Partnerships
Danish pharma Lundbeck A/S announced Oct. 14 that it established a research center in Shanghai to increase its footprint in the largest emerging market and better position itself for more partnerships in China
Lundbeck Establishes Shanghai Research Center To Find More Chinese Partnerships
Danish pharma Lundbeck A/S announced Oct. 14 that it established a research center in Shanghai to increase its footprint in the largest emerging market and better position itself for more partnerships in China
China's Largest Pharma Promoter CMS Outpaced Market With Unique Specialty Pharma Focus
SHANGHAI - China Medical System Holdings, the largest third-party promotion service company in China, differs from its competitors by targeting small- and mid-size specialty pharma as clients, giving the company more secure contracts, higher profile products and bigger margins